menu
    • menu

    Company profile for Cadrenal Therapeutics

    NEW Drugs in Dev.: 1
    Evonik

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    Contact Supplier

    End-to-end drug development, specializing in high-potency softgels and liquids, providing global partners with a competitive advantage.

    Virtual Booth

    Contact Supplier

    Kewpie is your partner for Sodium Hyaluronate & Hyaluronic Acid// CEP, USDMF, KDMF & JDMF registered.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    We are a clinical-stage biopharmaceutical company focused on advancing the development of our lead drug candidate, tecarfarin, a late-stage novel therapy with orphan drug indication for the prevention of systemic thromboembolism in patients with end-stage renal disease and atrial fibrillation. We are committed to bringing this novel therapy to the market to help improve the lives of the thousands of individuals who suffer fr...
    We are a clinical-stage biopharmaceutical company focused on advancing the development of our lead drug candidate, tecarfarin, a late-stage novel therapy with orphan drug indication for the prevention of systemic thromboembolism in patients with end-stage renal disease and atrial fibrillation. We are committed to bringing this novel therapy to the market to help improve the lives of the thousands of individuals who suffer from this very serious condition. Our mission is to build a company with a foundation of product candidates that significantly improve quality of life and patient outcomes for individuals with cardiorenal diseases.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Cadrenal TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    822 North A1A Ponte Vedra, FL 32082
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.cadrenal.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/cadrenal/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Cadrenal's Pipeline Shifts Towards Emergency Response System
    Cadrenal's Pipeline Shifts Towards Emergency Response System

    30 Dec 2025

    // ACCESSWIRE

    https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/cadrenals-pipeline-looks-less-like-a-microcap-and-more-like-an-emerge-1121792

    ACCESSWIRE
    30 Dec 2025
    Share Share
    Cadrenal Revitalizes Overlooked Anticoagulation Areas
    Cadrenal Revitalizes Overlooked Anticoagulation Areas

    29 Dec 2025

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2025-12-29/cadrenal-is-rebuilding-the-parts-of-anticoagulation-everyone-else-gave-up-on

    PHARMIWEB
    29 Dec 2025
    Share Share
    Cadrenal Therapeutics To Host Meetings At J.P. Morgan Healthcare
    Cadrenal Therapeutics To Host Meetings At J.P. Morgan Healthcare

    17 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/17/3207020/0/en/Cadrenal-Therapeutics-to-Conduct-Partnering-and-Investor-Meetings-During-the-J-P-Morgan-44th-Annual-Healthcare-Conference-in-San-Francisco-on-January-12-15-2026.html

    GLOBENEWSWIRE
    17 Dec 2025
    Share Share
    Cadrenal Therapeutics Acquires Phase 2 12-LOX Inhibitor VLX-1005
    Cadrenal Therapeutics Acquires Phase 2 12-LOX Inhibitor VLX-1005

    12 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/11/3203875/0/en/Cadrenal-Therapeutics-Acquires-VLX-1005-a-First-in-Class-Phase-2-12-LOX-Inhibitor-for-Patients-with-Heparin-Induced-Thrombocytopenia-HIT.html

    GLOBENEWSWIRE
    12 Dec 2025
    Share Share
    Cadrenal Expands Anticoagulation Platform In $40B Market
    Cadrenal Expands Anticoagulation Platform In $40B Market

    12 Dec 2025

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2025-12-12/cadrenals-anticoagulation-platform-is-expanding-in-a-40-billion-market

    PHARMIWEB
    12 Dec 2025
    Share Share
    Cadrenal's Quiet Expansion Play Is Starting To Get Loud
    Cadrenal's Quiet Expansion Play Is Starting To Get Loud

    12 Dec 2025

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2025-12-12/cadrenals-quiet-expansion-play-is-starting-to-get-loud

    PHARMIWEB
    12 Dec 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search